权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Randomized Controlled Trial of Macrolide Therapy for Mycoplasma pneumoniae

大环内酯类药物治疗肺炎支原体的随机对照试验

基本信息

批准号：
10620551
负责人：
Lilliam Ambroggio
金额：
$ 26.69万
依托单位：
UNIVERSITY OF COLORADO DENVER
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-07-01 至 2024-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10620551
关键词：
Absenteeism at work Address Adverse effects Adverse event Amoxicillin Ampicillin Antibiotic Resistance Antibiotic Therapy Antibiotics Azithromycin Bacterial Infections Breathing Child Childhood Clinical Clinical Trials Combined Modality Therapy Consumption Coughing Data Development Diagnosis Disease Double-Blind Method Effectiveness Fever Future Hospitalization Hospitalized Child Hospitals Incidence Individual Infection Japan Low Grade Fever Macrolide-resistance Macrolides Multicenter Studies Multicenter Trials Mycoplasma pneumonia infection Mycoplasma pneumoniae Nature Outcome Pathogen detection Patient-Focused Outcomes Patients Pediatric Hospitals Physical Function Placebos Pneumonia Prevalence Protocols documentation Public Health Quality of life Randomized Randomized, Controlled Trials Recommendation Recovery Reporting Research Personnel Resolution Respiratory Signs and Symptoms Risk Safety Schools Secondary to Streptococcus pneumoniae Symptoms Time Wheezing accurate diagnosis antimicrobial arm bacterial community beta-Lactams community acquired pneumonia comparative efficacy compare effectiveness cost cost effectiveness effectiveness evaluation efficacy evaluation experience improved in vitro activity overtreatment pathogen phase III trial prevent protocol development response side effect targeted treatment

项目摘要

PROJECT SUMMARY Community-acquired pneumonia (CAP) is the fifth most prevalent but second most costly reason for hospitalization in children. Mycoplasma pneumoniae (Mp) is the most frequently detected pathogen cause bacterial CAP. Although macrolides are recommended for the treatment of Mp CAP there is a lack of clear evidence to support macrolide treatment for Mp has which has likely led to the overuse of macrolides. This R34 application, “Randomized Controlled Trial of Macrolide Therapy for Mp”, will aide in the development of the full protocol and relevant documents for the future trial. In the future trial, we will randomize children who are hospitalized with Mp CAP to receive beta-lactam and azithromycin or beta-lactam and placebo. This trial will provide the necessary evidence for targeted therapy in children hospitalized with Mp CAP, leading to the use of necessary therapy while preventing over-treatment and decreasing complications for children with this prevalent disease.

项目摘要社区获得性肺炎（CAP）是第五大最流行但第二大最昂贵的原因，儿童住院。肺炎支原体（Mp）是最常见的病原体，细菌CAP尽管大环内酯类药物被推荐用于治疗Mp CAP，但缺乏明确的有证据支持大环内酯类药物治疗MP，这可能导致大环内酯类药物的过度使用。R34 应用程序，“随机对照试验的大环内酯类药物治疗MP”，将有助于发展的全面研究方案和未来试验的相关文件。在未来的试验中，我们将随机选择 Mp CAP住院接受β-内酰胺和阿奇霉素或β-内酰胺和安慰剂。本试验将为Mp CAP住院儿童的靶向治疗提供必要的证据，导致使用必要的治疗，同时防止过度治疗和减少并发症的儿童，这流行病。